Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 8, 2023 21:34 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 583 | $147.86 | $86,202.38 |
DisclosureSEC source: 0001022079-23-000066 · wf-form4_167831125235378.xml · nonDerivative · entry 2 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,241 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:34 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantCommon Stock | 1,985 | $147.86 | $293,502.10 |
DisclosureSEC source: 0001022079-23-000066 · wf-form4_167831125235378.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,824 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC |
RUSCKOWSKI STEPHEN HDirector
|
Tax withholdingCommon Stock | 38,604 | $147.86 | $5,707,987.44 |
DisclosureSEC source: 0001022079-23-000064 · wf-form4_167831097116995.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,597 F1 · security: Represents an award of restricted share units granted on February 25, 2013. F3 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC |
RUSCKOWSKI STEPHEN HDirector
|
GrantCommon Stock | 82,631 | $147.86 | $12,217,819.66 |
DisclosureSEC source: 0001022079-23-000064 · wf-form4_167831097116995.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,201 F1 · security: Represents an award of restricted share units granted on February 25, 2013. F2 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 22:08 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
SaleCommon Stock | 717 | $140.63 | $100,831.71 |
DisclosureSEC source: 0001022079-23-000054 · wf-form4_167814051080087.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,810 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 27, 2022. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:51 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 593 | $138.54 | $82,154.22 |
DisclosureSEC source: 0001022079-23-000050 · wf-form4_167788026089741.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,527 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 27, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:56 UTC |
RUSCKOWSKI STEPHEN HDirector
|
Tax withholdingCommon Stock | 3,496 | $140.69 | $491,852.24 |
DisclosureSEC source: 0001022079-23-000052 · wf-form4_167788053093571.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,570 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:51 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 320 | $140.69 | $45,020.80 |
DisclosureSEC source: 0001022079-23-000050 · wf-form4_167788026089741.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,120 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:47 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 90 | $140.69 | $12,662.10 |
DisclosureSEC source: 0001022079-23-000048 · wf-form4_167788002111009.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,566 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:42 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 68 | $140.69 | $9,566.92 |
DisclosureSEC source: 0001022079-23-000046 · wf-form4_167787971519132.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,260 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:40 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 65 | $140.69 | $9,144.85 |
DisclosureSEC source: 0001022079-23-000044 · wf-form4_167787957832714.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,839 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:37 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
Tax withholdingCommon Stock | 392 | $140.69 | $55,150.48 |
DisclosureSEC source: 0001022079-23-000042 · wf-form4_167787941666016.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,527 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:34 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 1,292 | $140.69 | $181,771.48 |
DisclosureSEC source: 0001022079-23-000040 · wf-form4_167787924588529.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,466 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 27, 2023 Filed Feb 27, 2023 21:42 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 15,167 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000030 · wf-form4_167753410682903.xml · derivative · entry 5 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,167 Underlying: Common Stock · 15,167 shares Expires 2033-02-23 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 24, 2023 Filed Feb 27, 2023 21:49 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 1,415 | $141.42 | $200,109.30 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,440 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 27, 2022. Read SEC document |
| February 24, 2023 Filed Feb 27, 2023 21:42 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
SaleCommon Stock | 1,690 | $141.42 | $238,999.80 |
DisclosureSEC source: 0001022079-23-000030 · wf-form4_167753410682903.xml · nonDerivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,919 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 27, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:56 UTC |
Davis J. E.Director · CEO and President
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 68,956 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000038 · wf-form4_167753497328240.xml · derivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,956 Underlying: Common Stock · 68,956 shares Expires 2033-02-23 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:56 UTC |
Davis J. E.Director · CEO and President
|
GrantCommon Stock | 17,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000038 · wf-form4_167753497328240.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,758 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:56 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 1,473 | $147.86 | $217,797.78 |
DisclosureSEC source: 0001022079-23-000038 · wf-form4_167753497328240.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,315 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:54 UTC |
RUSCKOWSKI STEPHEN HDirector
|
GrantCommon Stock | 20,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000037 · wf-form4_167753483583104.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,066 F2 · security: Represents an award of restricted share units granted on February 25, 2013. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:54 UTC |
RUSCKOWSKI STEPHEN HDirector
|
Tax withholdingCommon Stock | 5,826 | $147.86 | $861,432.36 |
DisclosureSEC source: 0001022079-23-000037 · wf-form4_167753483583104.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,007 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:50 UTC |
SAMAD SAMExecutive Vice President & CFO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 18,616 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000036 · wf-form4_167753460967466.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,616 Underlying: Common Stock · 18,616 shares Expires 2033-02-23 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:50 UTC |
SAMAD SAMExecutive Vice President & CFO
|
GrantCommon Stock | 4,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000036 · wf-form4_167753460967466.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,384 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 9,653 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · derivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2033-02-23 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 2,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,855 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 811 | $147.86 | $119,914.46 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,413 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:47 UTC |
Plewman PatrickSVP for Diagnostic Services
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 7,584 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000034 · wf-form4_167753444852146.xml · derivative · entry 3 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Underlying: Common Stock · 7,584 shares Expires 2033-02-23 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:47 UTC |
Plewman PatrickSVP for Diagnostic Services
|
GrantCommon Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000034 · wf-form4_167753444852146.xml · nonDerivative · entry 2 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,656 F3 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:47 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 245 | $147.86 | $36,225.70 |
DisclosureSEC source: 0001022079-23-000034 · wf-form4_167753444852146.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,737 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:46 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 1,960 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000033 · wf-form4_167753435928565.xml · derivative · entry 4 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 Underlying: Common Stock · 1,960 shares Expires 2033-02-23 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:46 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
GrantCommon Stock | 498 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000033 · wf-form4_167753435928565.xml · nonDerivative · entry 2 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,328 F2 · security: Represents an award of restricted share units. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:46 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 188 | $147.86 | $27,797.68 |
DisclosureSEC source: 0001022079-23-000033 · wf-form4_167753435928565.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,825 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:45 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 8,270 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000032 · wf-form4_167753428265779.xml · derivative · entry 5 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,270 Underlying: Common Stock · 8,270 shares Expires 2033-02-23 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:45 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000032 · wf-form4_167753428265779.xml · nonDerivative · entry 2 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,904 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:45 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 195 | $147.86 | $28,832.70 |
DisclosureSEC source: 0001022079-23-000032 · wf-form4_167753428265779.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,810 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:43 UTC |
GARDNER MARK ASVP of Molecular Gen & Oncol
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 7,584 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000031 · wf-form4_167753420049725.xml · derivative · entry 2 GARDNER MARK A · CIK 0001955242 · SVP of Molecular Gen & Oncol 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Underlying: Common Stock · 7,584 shares Expires 2033-02-23 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:43 UTC |
GARDNER MARK ASVP of Molecular Gen & Oncol
|
GrantCommon Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000031 · wf-form4_167753420049725.xml · nonDerivative · entry 1 GARDNER MARK A · CIK 0001955242 · SVP of Molecular Gen & Oncol 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,921 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:42 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
GrantCommon Stock | 3,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000030 · wf-form4_167753410682903.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,609 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:42 UTC |
Doherty Catherine T.SVP, Regional Businesses
|
Tax withholdingCommon Stock | 962 | $147.86 | $142,241.32 |
DisclosureSEC source: 0001022079-23-000030 · wf-form4_167753410682903.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Regional Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,771 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:39 UTC |
DELANEY MARK ESVP & Chief Commercial Officer
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 7,584 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000029 · wf-form4_167753393895974.xml · derivative · entry 2 DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Underlying: Common Stock · 7,584 shares Expires 2033-02-23 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:39 UTC |
DELANEY MARK ESVP & Chief Commercial Officer
|
GrantCommon Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000029 · wf-form4_167753393895974.xml · nonDerivative · entry 1 DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,650 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:38 UTC |
Plewman PatrickSVP for Diagnostic Services
|
OtherCommon Stock | 27 | $146.75 | $3,962.14 |
DisclosureSEC source: 0001022079-23-000011 · wf-form4_167546032206581.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,982 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 3. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:40 UTC |
Gregg Vicky BDirector
|
OtherCommon Stock | 64 | $146.75 | $9,391.74 |
DisclosureSEC source: 0001022079-23-000012 · wf-form4_167546039141816.xml · nonDerivative · entry 1 Gregg Vicky B · CIK 0001510304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,130 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:36 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
OtherCommon Stock | 13 | $146.75 | $1,907.70 |
DisclosureSEC source: 0001022079-23-000010 · wf-form4_167546012705026.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 3. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:29 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 267 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000002 · wf-form4_167286773766816.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,081.503 Underlying: Common Stock · 267 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:40 UTC |
RING TIMOTHY MDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,053 | $53.13 Strike: $53.13 | $55,940.63 |
DisclosureSEC source: 0001022079-22-000170 · wf-form4_167027641356305.xml · derivative · entry 5 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,053 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:40 UTC |
RING TIMOTHY MDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 972 | $62.01 Strike: $62.01 | $60,273.72 |
DisclosureSEC source: 0001022079-22-000170 · wf-form4_167027641356305.xml · derivative · entry 4 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 972 shares Expires 2023-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:40 UTC |
RING TIMOTHY MDirector
|
SaleCommon Stock | 2,025 | $152.50 | $308,812.50 |
DisclosureSEC source: 0001022079-22-000170 · wf-form4_167027641356305.xml · nonDerivative · entry 3 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,149 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:40 UTC |
RING TIMOTHY MDirector
|
Exercise / conversionCommon Stock | 1,053 | $53.13 | $55,940.63 |
DisclosureSEC source: 0001022079-22-000170 · wf-form4_167027641356305.xml · nonDerivative · entry 2 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:40 UTC |
RING TIMOTHY MDirector
|
Exercise / conversionCommon Stock | 972 | $62.01 | $60,273.72 |
DisclosureSEC source: 0001022079-22-000170 · wf-form4_167027641356305.xml · nonDerivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.